Patents by Inventor Argyrios Georgios Arvanitis

Argyrios Georgios Arvanitis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azolo triazines and pyrimidines
    Patent number: 7678793
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: March 16, 2010
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Liqi He, Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis
  • Azolo triazines and pyrimidines
    Patent number: 7094782
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: August 22, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liqi He, Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis
  • Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
    Publication number: 20030114468
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula (I): 1
    Type: Application
    Filed: November 7, 2001
    Publication date: June 19, 2003
    Inventors: Richard Gerald Wilde, Rajagopal Bakthavatchalam, James Peter Beck, Argyrios Georgios Arvanitis
  • Arylamino fused pyridines
    Patent number: 6448261
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I; and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: September 10, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson
  • Azolo triazines and pyrimidines
    Patent number: 6358950
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: March 19, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Liqi He, Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis
  • 1N-alkyl-n-arylpyrimidinamines and derivatives thereof
    Patent number: 6342503
    Abstract: The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer'disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R4, R5, Z, Y, V, X, X′, J, K, L, and M are as defined herein.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: January 29, 2002
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Paul Edward Aldrich, Argyrios Georgios Arvanitis, Robert Scott Cheeseman, Robert John Chorvat, Thomas Eugene Christos, Paul Joseph Gilligan, Dimitri Emil Grigoriadis, Carl Nicholas Hodge, Paul John Krenitsky, Everett Latham Scholfield, Sang William Tam, Zelda Rakowitz Wasserman
  • Tetrazine bicyclic compounds
    Patent number: 6313124
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: November 6, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Liqi He, Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis
  • Triazinones and derivatives thereof
    Patent number: 6218391
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I) and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorders, supranuclear palsy and eating disorders.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: April 17, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Argyrios Georgios Arvanitis, Richard E. Olson, Charles R. Arnold, III, William E. Frietze
  • Azolo triazines and pyrimidines
    Patent number: 6191131
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: February 20, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Liqi He, Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis
  • Pyrazinones and triazinones and their derivatives thereof
    Patent number: 6159980
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I) ##STR1## and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorders, supranuclear palsy and eating disorders.
    Type: Grant
    Filed: September 15, 1997
    Date of Patent: December 12, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: Argyrios Georgios Arvanitis, Richard E. Olson, Charles R. Arnold, III, William E. Frietze
  • Azolo triazines and pyrimidines
    Patent number: 6124289
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: ##STR1## and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivityassociated with psychopathological disturbance andstress.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: September 26, 2000
    Assignee: Dupont Pharmaceuticals Co.
    Inventors: Liqi He, Paul Joseph Gilligan, Argyrios Georgios Arvanitis, Robert John Chorvat
  • 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
    Patent number: 6107301
    Abstract: The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: ##STR1## wherein R.sup.1, R.sup.3, R.sup.4, R.sup.5, Z, Y, V, X, X', J, K, L, and M are as defined herein.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: August 22, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: Paul Edward Aldrich, Argyrios Georgios Arvanitis, Rajagopal Bakthavatchalam, James Peter Beck, Robert Scott Cheeseman, Robert John Chorvat, Paul Joseph Gilligan, Carl Nicholas Hodge, Zelda Rakowitz Wasserman
  • Arylamino fused pyrimidines
    Patent number: 6107300
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or formula II: ##STR1## and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: August 22, 2000
    Assignee: Dupont Pharmaceuticals
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson
  • Azolo triazines and pyrimidines
    Patent number: 6060478
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: ##STR1## and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: May 9, 2000
    Assignee: DuPont Pharmaceuticals
    Inventors: Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis